Clinical Research Directory
Browse clinical research sites, groups, and studies.
Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management
Sponsor: Stanford University
Summary
The goal of this clinical trial is to learn if a non-opioid pain medicine called suzetrigine can lower how much opioid pain medicine adults need after tonsil surgery (tonsillectomy) or a similar throat surgery.
Official title: STOP Trial (Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
58
Start Date
2026-11
Completion Date
2027-07
Last Updated
2026-09-16
Healthy Volunteers
No
Interventions
Suzetrigine
Suzetrigine is administered at its FDA-approved dose for moderate-to-severe acute pain: a 100 mg oral loading dose followed by 50 mg orally every 12 hours. No dose modification, dose escalation, or novel route is used; the trial therefore does not involve a dosage level or route that would increase risk relative to approved labeling, which is one of the conditions supporting IND exemption under 21 CFR 312.2(b).
Acetaminophen
Acetaminophen 1,000 mg every 6 hours (maximum 4,000 mg/24 h)
oxycodone
Oxycodone 5-10 mg every 4-6 hours
Locations (1)
Stanford University
Palo Alto, California, United States